Skip to main content
SpringerLink
Log in

Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies

  • Chapter
Therapy for Genitourinary Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 59))

  • 37 Accesses

Abstract

Tumor necrosis factor (TNF) was first described in 1975 [1] as a soluble factor appearing in the serum of mice treated with BCG and endotoxin. This factor received its name because it caused the hemorrhagic necrosis of a transplantable sarcoma in mice. Subsequently, TNF was found to be a protein secreted by activated macrophages and was described in virtually all vertebrate animals, including humans. TNF was purified and the gene for human TNF was cloned and expressed in bacteria, making available large quantities of purified recombinant human TNF (rTNF) [2–4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carswell EA, Old LJ, Kasel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 72:3666–3670,1975.

    Article  PubMed  CAS  Google Scholar 

  2. Pennica D, Hayfiick JS, Bringman TS, Palladino MA, Goeddel DV: Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA, 82:6060–6064, 1985.

    Article  PubMed  CAS  Google Scholar 

  3. Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF: Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228:149–154, 1985.

    Article  PubMed  CAS  Google Scholar 

  4. Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB: Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 313:803–806, 1985.

    Article  PubMed  CAS  Google Scholar 

  5. Alexander RB, Rosenberg SA: Tumor necrosis factor: Clinical applications. In: DeVita VT, Hellman S, Rosenberg SA (eds). Biologic Therapy of Cancer: Principles and Practice. J.B. Lippincott, Philadelphia, 1990.

    Google Scholar 

  6. Mclntosh JK, Mulé JJ, Merino MJ, Rosenberg SA: Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Res 48:4011–4017, 1988.

    Google Scholar 

  7. Stone-Wolff DS, Yip YK, Kelker HC, Le J, Henriksen-Destefano D, Rubin BY, Rinderknecht E, Aggarwal BB, Vilcěk J: Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med 159:828–843, 1984.

    Article  PubMed  CAS  Google Scholar 

  8. Aggarwal BB, Eessalu TE, Hass PE: Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 318:665–667, 1985.

    Article  PubMed  CAS  Google Scholar 

  9. Kavoussi LR, Ruesing RA, Hudson MA, Catalona WJ, Ratliff TL: Effect of tumor necrosis factor and interferon gamma on human renal carcinoma cell line growth. J Urol 142:875–878, 1989.

    PubMed  CAS  Google Scholar 

  10. Mclntosh JK, Mulé JJ, Krosnick JA, Rosenberg SA: Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res 49:1408–1414, 1989.

    Google Scholar 

  11. Ruff MR, Gifford GE: Tumor necrosis factor. In: Pick E (ed). Lymphokines, Vol. 2. Academic Press, New York, 1981, pp. 235–271.

    Google Scholar 

  12. Alexander RB, Nelson WG, Coffey DS: Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 47:2403–2406, 1987.

    PubMed  CAS  Google Scholar 

  13. Alexander RB, Isaacs JT, Coffey DS: Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. J Urol 138:427–429, 1987.

    PubMed  CAS  Google Scholar 

  14. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cortran RS, Gimbrone MA, Jr.: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 83:4533–4537, 1986.

    Article  PubMed  CAS  Google Scholar 

  15. Stolpen AH, Guinan EC, Fiers W, Pober JS: Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 123:16–24, 1986.

    PubMed  CAS  Google Scholar 

  16. Tennenberg SD, Solomkin JS: Activation of neutrophils by cachectin/tumor necrosis factor: Priming of N-formyl-methionyl-leucyl-phenylalanine-induced oxidative responsiveness via receptor mobilization without degranulation. J Leuk Biol 47:217–223, 1990.

    CAS  Google Scholar 

  17. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871, 1985.

    Article  PubMed  CAS  Google Scholar 

  18. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486, 1988.

    Article  PubMed  CAS  Google Scholar 

  19. Levine B, Kaiman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heat failure. N Engl J Med 323:236–241, 1990.

    Article  PubMed  CAS  Google Scholar 

  20. Rook GAW, Taverne J, Moreno C: The role of tumor necrosis factor in the pathogenesis of tuberculosis and leprosy and the relationship between tissue-damaging pathology and production of agalactosyl IgG. In: Bonavida B, Granger G (eds). Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy. Karger, Basel, 1990, pp. 168-176.

    Google Scholar 

  21. Creasey AA, Reynolds MT, Laird W: Cures and Partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 46:5687–5690, 1986.

    PubMed  CAS  Google Scholar 

  22. Mulé JJ, Asher A, McIntosh J, Lafreniere R, Shiloni E, Lefor A, Reichert CM, Rosenberg SA: Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: Tumor size influences the response to therapy. Cancer Immunol Immunother 26:202–208, 1988.

    PubMed  Google Scholar 

  23. Mclntosh JK, Mulé JJ, Travis WD, Rosenberg SA: Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. Cancer Res 50:2463–2469, 1990.

    Google Scholar 

  24. Asher AL, Mulé JJ, Rosenberg SA: Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. Cancer Immunol Immunother 28:153–156, 1989.

    Article  PubMed  CAS  Google Scholar 

  25. Havell EA, Fiers W, North RJ: The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167:1067–1085, 1988.

    Article  PubMed  CAS  Google Scholar 

  26. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Jr., Shepard HM: Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230:943–945, 1985.

    Article  PubMed  CAS  Google Scholar 

  27. Ostrove JM, Gifford GE: Stimulation of RNA synthesis in L929 cells by rabbit tumor necrosis factor. Proc Soc Exp Biol Med 160:354–358, 1979.

    PubMed  CAS  Google Scholar 

  28. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468, 1984.

    Article  PubMed  CAS  Google Scholar 

  29. Liu LF: DNA topoisomerases — enzymes that catalyze the breaking and rejoining of DNA. CRC Crit Rev Biochem 15:1–24, 1983.

    Article  PubMed  CAS  Google Scholar 

  30. D’Arpa P, Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163–177, 1989.

    Google Scholar 

  31. Pienta KJ, Partin AW, Coffey DS: Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 49:2525–2532, 1989.

    PubMed  CAS  Google Scholar 

  32. Fruehauf JP, Myers CE, Sinha BK: Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 82:1206–1209, 1990.

    Article  PubMed  CAS  Google Scholar 

  33. Bahnson RR, Ratliff TL: In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). J Urol 144:172–175, 1990.

    PubMed  CAS  Google Scholar 

  34. Gapany M, Dawson DE, Schriever C, Burgess R, Gipple JR, Riggs CE, Jr.: Tumor necrosis factor and cytotoxic agents. Effect on squamous carcinoma lines. Arch Otolaryngol Head Neck Surg 116: 436–439,1990.

    Article  PubMed  CAS  Google Scholar 

  35. Giaccone G, Kadoyama C, Maneckjee R, Venzon D, Alexander RB, Gazdar AF: Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines. Int J Cancer 46:326–329, 1990.

    Article  PubMed  CAS  Google Scholar 

  36. Iizumi T, Yazaki T, Waku M, Soma G: Immunochemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and hyperthermia. J Urol 142:386–389, 1989.

    PubMed  CAS  Google Scholar 

  37. Krosnick JA, Mule JJ, Mclntosh JK, Rosenberg SA: Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 49:3729–3733, 1989.

    PubMed  CAS  Google Scholar 

  38. Bloom ND, Norbergs DA, Sherman B, Sadjadi M, Ramaswamy G, Jacobs R, Ackerman N: Augmentation of the effect of doxorubicin with low-dose tumor necrosis factor in experimental liver metastasis. Mol Biother 2:121–124, 1990.

    PubMed  CAS  Google Scholar 

  39. Das AK, Walther PJ, Buckley NJ, Poulton SH: Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts. Arch Surg 124:107–110, 1989.

    Article  PubMed  CAS  Google Scholar 

  40. Donaldson JT, Keane TE, Poulton SH, Walther PJ: Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. Urol Res 18:245–250, 1990.

    CAS  Google Scholar 

  41. Burgers JK, Marshall FF, Isaacs JT: Enhanced anti-tumor effects of recombinant human tumor necrosis factor plus VP-16 on metastatic renal cell carcinoma in a xenograft model. J Urol 142:160–164, 1989.

    PubMed  CAS  Google Scholar 

  42. Schmid DS, Hornung R, McGrath KM, Paul N, Ruddle NH: Target cell DNA fragmentation is mediated by lymphotoxin and tumor necrosis factor. Lymphokine Res 6: 195–202, 1987.

    PubMed  CAS  Google Scholar 

  43. Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748–3753, 1990.

    PubMed  CAS  Google Scholar 

  44. Rubin BY, Anderson SL, Lunn RM, Hellermann GR, Smith LJ: Fragmentation of cellular DNA is a nonspecific indicator of responsiveness to tumor necrosis factor. J Biol Response Mod 8:553–559, 1989.

    PubMed  CAS  Google Scholar 

  45. Kyprianou N, Alexander RB, Isaacs JT: Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II targeted drugs in L929 cells. J Natl Cancer Inst 83:346–350, 1991.

    Article  PubMed  CAS  Google Scholar 

  46. Utsugi T, Mattern MR, Mirabelli CK, Hanna N: Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: Enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 50:2636–2640, 1990.

    PubMed  CAS  Google Scholar 

  47. Taylor C, Hersh E, Plezia P, Alberts D, McCloskey T, Wiggins C, Ahmann F, King D, Rudolph A: A phase I and pharmacokinetic study of recombinant tumor necrosis factor and doxorubicin (abstr.). Proc Am Soc Clin Oncol 8:183–183, 1989.

    Google Scholar 

  48. Orr D, Oldham R, Lewis M, Bertoli L, Birch R: Phase I study of the sequenced administration of etoposide and recombinant tumor necrosis factor in patients with advanced malignancy (Abstr.). Proc Am Soc Clin Oncol 8:190–190, 1989.

    Google Scholar 

  49. Simons JW, Rowinsky EK, McGuire WP, Fornastiere AA, Nelson WG, Ettinger DS, Grochow LB, Clarke BV, Lubejko BG, Duerr MT, Burgers JK, Marshall FF, Donehower RG: Phase I study of overlapping continuous infusion VP-16 and recombinant human tumor necrosis factor in advanced cancer (Abstr.). Proc Am Soc Clin Oncol 9:200–200, 1990.

    Google Scholar 

  50. Riggs CE, Davis RT, Ratain MJ, Schilsky R, Vogelzang NJ, Geick J, Jarnow L, O’Brien S, Denger P: Pharmacokinetics of adriamycin in combination with human tumor necrosis factor. Results from a phase I trial (Abstr.). Proc Am Assoc Cancer Res 31:179–179, 1990.

    Google Scholar 

  51. Kahn JO, Kaplan LD, Volberding PA, Ziegler JL, Crowe S, Saks SR, Abrams DI: Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi’s sarcoma: A randomized, double-blind trial. J Acquir Immune Defic Syndr 2:217–223, 1989.

    PubMed  CAS  Google Scholar 

  52. Bahnson RR, Ballou BT, Ernstoff MS, Cramer DV, Schwentker FN, Reiland JM, Hakala TR: Toxicity of intravesical recombinant human tumor necrosis factor in cynomolgus monkeys. J Biol Response Mod 9:445–447, 1990.

    PubMed  CAS  Google Scholar 

  53. Raeth U, Schmid H, Hofman J, Wiedenmann B, Kempeni J, Schlick E, Kaufmann M: Intraperitoneal application of recombinant tumor necrosis factor as an effective palliative treatment of malignant ascites from ovarian and gastroenteropancreatic carcinomas (Abstr.). Proc Am Soc Clin Oncol 8:181–181, 1989.

    Google Scholar 

  54. Kasid A, Morecki S, Aebersold P, Cornetta K, Culver K, Freeman S, Director E, Lotze MT, Blaese RM, Anderson WF, Rosenberg SA: Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 87:473–477, 1990.

    Article  PubMed  CAS  Google Scholar 

  55. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF: Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578, 1990.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urologic Oncology, Surgery Branch, National Cancer Institute, Bldg. 10, Room 2B56, Bethesda, MD, 20892, USA

    Richard B. Alexander (Senior Investigator)

Authors
  1. Richard B. Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, USA

    Herbert Lepor  & Russell K. Lawson  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Alexander, R.B. (1992). Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies. In: Lepor, H., Lawson, R.K. (eds) Therapy for Genitourinary Cancer. Cancer Treatment and Research, vol 59. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3502-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3502-7_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6553-2

  • Online ISBN: 978-1-4615-3502-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation